SANAHIGH SIGNALFINANCIAL10-K

SANA shows severe financial deterioration with a 97% collapse in capital expenditure, 44% cash burn, and 36% equity destruction while current liabilities surged 73%.

The dramatic reduction in capital spending suggests either severe cash constraints forcing the company to halt investments or a major strategic pivot away from asset-heavy operations. Combined with the substantial cash burn and equity decline, this indicates significant financial stress that could threaten the company's ability to fund its biotech operations and research pipeline.

Comparing 2026-03-03 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

SANA experienced severe financial deterioration across multiple metrics, with cash and equivalents plummeting 44% to $71.9M while current liabilities spiked 73% to $78.7M, creating a concerning liquidity squeeze. The company's balance sheet contracted significantly with total assets down 17% and stockholders' equity falling 36%, though R&D expenses were cut 39% and operating cash flow improved 36% as management appears to be implementing aggressive cost-cutting measures. The 97% collapse in capital expenditure from $33.4M to just $938K is particularly alarming, suggesting either severe cash constraints or a fundamental shift away from asset investments that could impair future growth prospects.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97.2%
$33.4M→$938K

Capex reduced 97.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+73.3%
$45.4M→$78.7M

Current liabilities surged 73.3% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-43.7%
$127.6M→$71.9M

Cash declined 43.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-39.3%
$217.6M→$132.0M

R&D spending cut 39.3% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-35.8%
$250.5M→$160.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+35.5%
-$223.2M→-$143.8M

Operating cash flow surged 35.5% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-16.8%
$501.0M→$416.9M

Total assets contracted 16.8% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-17
ADDED
As of February 24, 2026 , the Registrant had 266,866,897 shares of common stock, $0.0001 par value per share, outstanding.
Importantly, this summary does not address every aspect of our risk factors, all of the risks that we face, or other factors not presently known to us or that we currently believe are immaterial.
The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
Disruptions at these regulatory authorities could delay or otherwise hinder the regulatory approval process for our product candidates.
Business O verview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades.
+7 more — sign up free →
REMOVED
As of March 10, 2025, the Registrant had 225,024,899 shares of common stock, $0.0001 par value per share, outstanding.
Importantly, this summary does not address all of the risks that we face.
The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the United States Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
Overview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades.
We are developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →